Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection
about
Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C.Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patientsPopulation pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infectionFatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis COptimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.Treatment failure in hepatitis C: mechanisms of non-response.Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.The impact of ethnicity on hepatitis C virus treatment decisions and outcomes.Hepatitis C in African Americans.Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.
P2860
Q34262438-29971EF0-2FEE-4ABF-A321-5174831D7E48Q34788754-438F86DB-1C01-4F2D-A316-3766CBD6CB05Q36065593-9B2CCCB1-C5D9-41F6-8CD4-4BA355834A58Q36335752-53608B92-58E4-44E8-98B0-47E93F5265F0Q36418455-A4661F95-6185-4B73-AEE8-4F7B718E0619Q36667084-45EDCC8E-B9A7-4E15-9AA7-903D8330B24EQ36810865-B8D34716-FFFC-4112-8720-693317D544E0Q37032096-EA9CDC40-CB15-4DE2-B076-ACE85331282EQ37345286-56DB0FDA-B4C7-49FB-ADA2-0E0A445F81A8Q37449527-045BEDF5-9DC8-4ADF-A03E-A46DFE8F3627Q38052034-3FA1A50D-B7EB-4188-8A74-2102A4D89BD3Q41758808-B629BA94-F668-4F16-B6F2-295A29F9A5B8Q42199023-392C8BC3-6905-41D4-AB6A-92D02C7164D4Q43000694-67C0FE89-D71F-4532-9876-5ADC008A356EQ43001794-17938F07-CE47-4DEC-8D9B-6E4881216735Q46574035-B5632A40-99A7-4736-8604-1F506FC33BE1
P2860
Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@ast
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@en
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@nl
type
label
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@ast
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@en
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@nl
prefLabel
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@ast
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@en
Peginterferon Pharmacokinetics ...... s C Virus Genotype 1 Infection
@nl
P2093
P2860
P1476
Peginterferon pharmacokinetics ...... s C virus genotype 1 infection
@en
P2093
Charles D Howell
Jay H Hoofnagle
Lennox Jeffers
Marika Paul
Milton Taylor
Norah A Terrault
Virahep-C Study Group
P2860
P304
P356
10.1016/J.CGH.2008.02.035
P407
P577
2008-04-14T00:00:00Z